IRWD

Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc. (IRWD) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.4) C+ (2.5) A- (3.9) B (3.3) C+ (2.6) B (3.2)
2026-11-05 B (3.4) B- (3.0) A- (3.9) C (2.5) C+ (2.7) B- (3.1)
2026-10-29 B (3.4) B- (2.9) A- (4.0) B- (2.9) C+ (2.7) B (3.2)
2026-10-22 B (3.4) B- (2.9) A- (4.0) B- (2.9) C+ (2.6) B (3.2)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe